Global De-identified Health Data Market Size Study, By Type of Data (Clinical Data, Genomic Data, Patient Demographics, Prescription Data, Others), By Application (Clinical Research and Trials, Drug Discovery, Public Health, Others), By End-use (Pharmaceu

The global de-identified health data market was valued at approximately USD 7.42 billion in 2023 and is anticipated to grow at a CAGR of 9.07% over the forecast period of 2024-2032. This expansion is largely attributed to the increasing integration of AI and machine learning in healthcare analytics, which enables organizations to leverage privacy-compliant data for large-scale clinical studies, predictive modeling, and pharmaceutical R&D. The proliferation of electronic health records (EHRs), wearable health devices, and genomic sequencing initiatives has further widened the applications of de-identified datasets, ensuring regulatory compliance while optimizing healthcare delivery and drug development processes.

Regulatory mandates such as HIPAA (Health Insurance Portability and Accountability Act) in the U.S. and GDPR (General Data Protection Regulation) in Europe have compelled healthcare organizations to de-identify patient data while maintaining data utility for research. This has led to significant investments in secure data-sharing platforms and federated learning models, enabling researchers to extract actionable insights without compromising patient confidentiality. For instance, in April 2023, Philips and MIT’s Institute for Medical Engineering and Science (IMES) collaborated to develop an enhanced critical care dataset, integrating de-identified ICU patient data to support clinical AI applications and patient outcome improvement.

Moreover, the growing number of partnerships between pharmaceutical firms, research institutions, and health-tech companies is accelerating the adoption of de-identified data for drug discovery and precision medicine. In December 2023, nference partnered with Emory Healthcare to create a federated network of de-identified data aimed at improving disease modeling and enhancing diagnostic precision. The increasing reliance on real-world evidence (RWE) to optimize treatment pathways and reduce trial costs is expected to be a key driver for market growth over the coming years.

North America currently dominates the market, accounting for over 31.53% of the global revenue in 2024, due to the presence of advanced health data infrastructure, AI-driven analytics adoption, and regulatory frameworks supporting data de-identification. Europe follows closely, with strong government-backed initiatives in health data research, while Asia-Pacific is projected to experience the fastest CAGR, driven by digital transformation in healthcare, rising investments in health IT, and an increasing focus on AI-driven medical research.

Major Market Players Included in This Report Are:
• IQVIA
• Oracle (Cerner Corporation)
• Merative (Truven Health Analytics)
• Optum, Inc. (UnitedHealth Group)
• ICON plc
• Veradigm LLC (formerly Allscripts)
• IBM
• Flatiron Health (F. Hoffmann-La Roche Ltd)
• Premier, Inc.
• Shaip
• Komodo Health, Inc.
• Evidation Health, Inc.
• Medidata
• Clarify Health Solutions
• Satori Cyber Ltd.

The Detailed Segments and Sub-Segment of the Market Are Explained Below:

By Type of Data:
• Clinical Data
• Genomic Data
• Patient Demographics
• Prescription Data
• Claims Data
• Behavioral Data
• Wearable and Sensor Data
• Survey and Patient-Reported Data
• Imaging Data
• Laboratory Data
• Hospital and Provider Data
• Social Determinants of Health (SDoH) Data
• Pharmacogenomic Data
• Biometric Data
• Operational and Financial Data
• Epidemiological Data
• Healthcare Utilization Data
• Others

By Application:
• Clinical Research and Trials
• Public Health
• Precision Medicine
• Health Economics and Outcomes Research (HEOR)
• Population Health Management
• Drug Discovery and Development
• Healthcare Quality Improvement
• Insurance Underwriting and Risk Assessment
• Market Access and Commercial Strategy
• Business Intelligence and Operational Efficiency
• Telemedicine and Remote Monitoring
• Patient Engagement and Support Programs
• Others

By End-Use:
• Pharmaceutical Companies
• Biotechnology Firms
• Medical Device Manufacturers
• Healthcare Providers
• Insurance Companies/Healthcare Payers
• Research Institutions
• Government Agencies
• Others

By Region:

North America:
• U.S.
• Canada
• Mexico

Europe:
• UK
• Germany
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway

Asia-Pacific:
• Japan
• China
• India
• Australia
• South Korea
• Thailand

Latin America:
• Brazil
• Argentina

Middle East & Africa:
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Years Considered for the Study Are as Follows:
• Historical Year: 2022-2023
• Base Year: 2023
• Forecast Period: 2024-2032

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2024 to 2032
• Annualized revenues and regional-level analysis for each market segment
• Detailed analysis of geographical landscape with country-level market insights
• Competitive landscape with key company profiling and revenue share analysis
• Assessment of key business strategies and investment opportunities in the market
• Demand-side and supply-side analysis of de-identified health data solutions

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.